
Gilead NASH drug dead in the water as second Phase III trial fails
An analyst wrote that with selonsertib's failures in fourth- and now third-stage fibrosis, the drug will have no place in NASH treatment. Gilead has entered partnerships focused on other compounds for the fatty liver disease.